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Introduction

1
We rely heavily on the dwindling resource of crude petroleum to supply not only fuels but also 2 an array of valuable chemicals. Globally, roughly 20% of crude petroleum consumed is used for the 3 synthesis of products other than transportation and industrial fuels, a sizeable fraction of which are 4 petrochemicals [1] . Petrochemicals are used as raw materials in the manufacturing of a variety of 5 products such as polymers, textiles, paints, solvents, pharmaceuticals, detergents, waxes and lubricants 6 that find applications in our day-to-day lives. Reducing our dependence on petroleum by utilizing 7 biomass as a renewable resource requires an integrated approach towards engineering of 8 microorganisms into 'microbial chemical factories' (MCFs) that can be used in a 'biorefinery' for the 9 conversion of biomass into both fuels and value added biochemicals. Biosynthesis of high value chemical 10 compounds from biomass using natural or engineered pathways in microorganisms also serves as a 11 promising alternative to chemical synthesis processes that employ expensive, hazardous and non-12 renewable raw materials and reagents as well as harsh processing conditions. 13
The evolution of the field of metabolic engineering has led to the development of principles and 14 tools that enable construction and optimization of MCFs by tapping into naturally occurring pathways in 15 specific host organisms, heterologous expression of non-native pathways in well-characterized hosts, or 16 engineering de novo biosynthetic pathways for synthesis of various natural and non-natural products. De 17 novo pathway engineering refers to the design and construction of novel pathways (hitherto unknown in 18 nature in any single organism) by assembling multiple existing partial pathways from different organisms 19 or using promiscuous or engineered enzymes as biocatalysts to catalyze a series of biotransformations 20 with non-natural substrates [2*]. This capability is of particular importance for truly expanding the 21 repertoire of value added products that can be synthesized microbially. 22 Figure 1 outlines the steps involved in the design of novel pathways for MCFs and various tools 23 and approaches used for their optimization. Once a pathway has been designed and selected for 24 [15] and plant secondary metabolites such as flavanoids, stilbenoids [16] and isoprenoids [14, 17] . In this 1 review, we visit some recent studies focusing on the design, engineering and optimization of MCFs for 2 synthesis of value-added products, with particular emphasis on exploiting enzyme promiscuity for de 3 novo pathway construction and engineering of pathway enzymes and cofactor balances to enhance 4 pathway productivity. 5
Exploiting enzyme promiscuity for design and engineering of novel pathways 6 All living cells metabolize a limited set of common metabolites into a wide range of molecules 7 essential for the sustenance of various life processes. The key to the generation of such molecular 8 diversity is the array of enzymes coded by the genomes, capable of catalyzing a wide variety of 9 biochemical transformations, often with more than one substrate. Enzyme promiscuity [18,19*] refers 10 to the ability to catalyze the same reactions with a variety of structurally and chemically similar 11 substrates (substrate promiscuity) or multiple different chemical reactions (catalytic promiscuity) 12 sharing certain mechanistic features and is critical for expanding natural cell metabolism for the 13 biosynthesis of valuable new chemicals. While the use of catalytic promiscuity for development of novel 14 biocatalysts has been extensively reviewed [20] [21] [22] , exploiting natural substrate promiscuity for catalysis 15 in novel pathways has received less attention. Indeed, many enzymes naturally exhibit a broad 16 substrate range by accommodating alternative molecules in their active site, a property that can be 17 effectively employed for catalysis with non-native substrates in novel pathways. 18
The Liao group at UCLA [23**,24**,25] has effectively employed such promiscuity for the 19 production of various non-natural alcohols and amino acids in E. coli from various 2-ketoacid 20 intermediates in the native branched chain amino acid synthesis pathways. The inherent ability of the 21 enzymes LeuA, LeuC and LeuD of the Leu operon to initiate chain elongation with their natural 22 substrate, 2-ketoisovalerate during L-leucine synthesis, was extended to the structurally similar natural 23 metabolite 2-keto-3-methylvalerate (precursor to L-isoleucine) followed by decarboxylation by the 1 broad substrate range enzyme 2-ketoisovalerate decarboxylase (KIVD) from Lactococcus lactis and 2 reduction by alcohol dehydrogenase VI (Adh6) from Saccharomyces cerevisiae Adh6 for synthesis of the 3 novel branched chain alcohol (S)-3-methyl-1-pentanol. In a separate study, the authors explored the 4 ability of the E. coli transaminase IlvE and valine dehydrogenases from various Streptomyces species to 5 catalyze amination of 2-ketobutyrate for the synthesis of the non-natural amino acid L-homoalanine 6
[24**]. Our group has effectively used enzyme promiscuity exhibited by enzymes of the butanol and 7 polyhydroxyalkanoate synthesis pathways from different organisms for the microbial synthesis of 8 enantiopure forms of the biodegradable polymer precursor 3-hydroxyvaleric acid as a value-added 9 product [9] . 10
In each of these studies, enzymes chosen to be tested for promiscuity were selected based on 11 knowledge of catalytic activity on structurally similar native substrates or functional groups. Screening of 12 multiple possible enzymes exhibiting the required biocatalytic activity from different organisms can be 13 an effective strategy for sampling different naturally evolved enzyme activities and specificities to 14 identify an enzyme exhibiting activity towards a required pathway intermediate. For Indeed, identification of candidate enzymes for novel pathways relies on continued investigation 10 of enzyme crystal structures and identification of catalytic active sites as well as development and 11 validation of reliable bioinformatics approaches for utilizing this information for a priori prediction of 12 enzyme activity and specificity. Simultaneously, the information garnered from the experimental 13 exploration of enzymes in novel pathways can in turn offer useful insights into enzyme catalytic activity 14 and serve to validate and refine the developed computational tools. Further, such substrate promiscuity 15 also serves as an excellent starting point for engineering novel biocatalysts with higher activity and 16 specificity towards the non-native substrates. 17
Enhancing pathway productivity through protein engineering coworkers demonstrated the implementation of such an integrated metabolic and protein engineering 6 approach for effectively enhancing titers of levopimaradiene (a valuable diterpenoid precursor to 7 pharmaceutical ginkgolides) over 2600-fold in E. coli by engineering the key rate limiting pathway 8 enzymes levopimaradiene synthase (LPS) and geranylgeranyl diphosphate synthase (GPPS) for increased 9 activity and specificity, in addition to amplifying fluxes towards the precursor metabolites isopentenyl 10 diphosphate (IPP) and dimethylallyl diphosphate (DMPP) [36**]. For evolution of GPPS exhibiting higher 11 activity towards geranylgeranyl diphosphate (GPP) synthesis from IPP and DMPP, random mutagenesis 12 using error prone PCR was used to create a library of GPPS mutants. Lycopene biosynthesis from GPP 13 was used as a colorimetric reporter for high throughput screening of this library for isolating an 14 improved GPPS variant. Yang and coworkers used directed evolution of the enzyme propionyl-CoA 15 transferase (Pct) from Clostridium propionicum to effectively activate lactate to lactyl-CoA to serve as a 16 substrate for microbial synthesis of the valuable polymer, polylactic acid (PLA) and other lactic acid co-17 polymers using an engineered PHA synthase [31,37*]. 18
Completely combinatorial strategies towards altering protein activity and specificity, such as 19 random mutagenesis or directed evolution do not require detailed enzyme crystal structure or active 20 site information, but are time consuming, laborious and often require several rounds of mutagenesis 21 and selection. They may also be impractical in the absence of high throughput screens or selection 22
strategies. While technologies such as MAGE [38] , TRMR [39] and SCALES [40] have thus far focused on 23
modifying regulatory regions to affect protein expression, they offer excellent practical solutions 24 towards accelerated directed evolution across multiple target loci simultaneously within a short period 1 of time. However, they still rely on high throughput screens to isolate improved mutant candidates. On 2 the other hand, site directed mutagenesis of select residues in the active site can limit the size of the 3 mutant library and obviates the need for a high throughput screen, but requires detailed information 4 about the active site and substrate-enzyme interaction to be derived from the enzyme crystal structure. 5
In the absence of such information for an enzyme of interest, constructing homology based crystal 6 structure models by threading residues of the enzyme of interest onto known crystal structures of 7 similar enzymes can allow identification of a putative active site. In the previously mentioned study on 8 levopimaradiene synthesis [36**], the authors used this approach to identify a putative active site for 9 the LPS enzyme and replaced individual residues in this active site with alternative residues from 10 paralogous LPS-type enzymes from other organisms, one at a time to sample alterations in activity and 11 specificity using the resulting distribution of levopimaradiene and by-products as a screen. Mutations in 12 residues that resulted in the most significant productivity enhancements were subjected to saturation 13 mutagenesis and were combined to engineer an LPS enzyme with 10-fold enhancement in 14 levopimaradiene productivity. 15
Protein engineering can also be employed for building on and improving naturally promiscuous 16 activities employed in novel pathways. Zhang and coworkers adopted this approach to enhance the 17 specificities of the enzymes LeuA and 2-ketoisovalerate decarboxylase (KIVD) toward the non-natural 18 substrates 2-keto-3-methylhexanoate and 2-keto-3-methylvalerate respectively by enlarging the 
Conclusions
20
Design, engineering and optimization of novel pathways expands the array of value added products that 21 can be synthesized from biomass as alternatives to petroleum derived chemicals. Successful 22 development of MCFs is essential to cope with our dwindling fossil resources but poses a number of 23 challenges, including lack of well characterized enzymes, poor activity of selected pathway enzymes, low 24 product titers, poor yield and selectivity, metabolic burden and unfavorable cofactor balance. Advances 1 in the fields of metabolic engineering, biochemistry, protein engineering and synthetic and molecular 2 biology have produced experimental and in silico tools to address these challenges. In the absence of a 3 large number of well-characterized enzymes, exploiting natural enzyme promiscuity is critical for design 4 of novel pathways. Protein engineering can further improve on such promiscuous activity and enhance 5 specificity and activity in natural and novel pathways to improve productivity. Cofactor balancing is 6 essential and can further result in several fold improvement in titers. Indeed, for synthesis of value 7 added chemicals using MCFs to be economically feasible and to compete favorably with chemical 8 synthesis, these approaches need to effectively complement conventional metabolic engineering efforts 9 in the design and engineering of pathways. 10
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The authors effectively employed both random mutagenesis (using a cleverly devised high 36 throughput screen) and site directed mutagenesis to enhance the activity and specificity of rate 37 limiting enzymes to complement conventional metabolic engineering precursor pool 38 enhancement to achieve a 2600-fold increase in the synthesis of the valuable pharmaceutical 39 precursor levopimaradiene. engineering novel or natural pathways for MCFs is to identify potential natural cell metabolites or 5 biomass derived feedstocks that can serve as starting materials and the series of biochemical reactions 6 required to convert these into the desired product. Martin and co-workers [3*] have reviewed some of 7 the computational tools available for identifying and selecting from the multiple possible pathways 8 connecting different starting materials to a product of interest. Once a pathway is selected, appropriate 9 natural enzymes expected to catalyze pathway reactions need to be selected using enzyme information 10 from various databases. In silico approaches such as protein blast searches and molecular docking may 11 help in such enzyme selection. Further pathway optimization to enhance product titers relies on an 12 integrated approach composed of 1) Metabolic Engineering to enhance precursor metabolite availability 13 using gene knockouts and enzyme expression level manipulation 2) Protein Engineering to enhance 14 pathway enzyme specificity and activity and 3) Cofactor Balancing via effective cofactor recycling. 15 
